A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC)

被引：5
|
作者：
Lenz, Heinz-Josef
Kasi, Anup
Mendelsohn, Lawrence
Cannon, Timothy Lewis
Starr, Jason S.
Hubbard, Joleen M.
Bekaii-Saab, Tanios S.
Ridinger, Maya
Samuelsz, Errin
Ruffner, Katherine L.
Erlander, Mark G.
Ahn, Daniel H.
机构：
[1] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA
[2] Univ Kansas, Ctr Canc, Westwood, KS USA
[3] Little Rock Hem Onc Assoc, Little Rock, AR USA
[4] Inova Schar Canc Inst, Fairfax, VA USA
[5] Univ Florida, Hlth Canc Ctr, Jacksonville, FL USA
[6] Mayo Clin, Rochester, MN USA
[7] Mayo Clin, Div Hematol Oncol, Phoenix, AZ USA
[8] Cardiff Oncol, San Diego, CA USA
[9] Mayo Clin, Phoenix, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.100
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
100
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+breast cancer (TBCRC 050).
    Stringer-Reasor, Erica Michelle
    Li, Yufeng
    Witherspoon, Felicia
    Specht, Jennifer M.
    Mesias, Jesus Del Santo Anampa
    Nanda, Rita
    Dees, Elizabeth Claire
    Wolff, Antonio C.
    Krop, Ian E.
    Lin, Nancy U.
    Rimawi, Mothaffar F.
    Yang, Eddy Shih-Hsin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC)
    Shergill, Ardaman
    Liao, Chih-Yi
    Kindler, Hedy L.
    Polite, Blase N.
    Catenacci, Daniel V. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [33] A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Albiruni R. Abdul Razak
    Hung-Ming Wang
    Jang-Yang Chang
    Myung-Ju Ahn
    Pamela Munster
    George Blumenschein
    Benjamin Solomon
    Darren Wan-Teck Lim
    Ruey-Long Hong
    David Pfister
    Nabil F. Saba
    Se-Hoon Lee
    Carla van Herpen
    Cornelia Quadt
    Douglas Bootle
    Lars Blumenstein
    David Demanse
    Jean-Pierre Delord
    Targeted Oncology, 2023, 18 : 853 - 868
  • [34] A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Razak, Albiruni R. Abdul
    Wang, Hung-Ming
    Chang, Jang-Yang
    Ahn, Myung-Ju
    Munster, Pamela
    Blumenschein Jr, George
    Solomon, Benjamin
    Lim, Darren Wan-Teck
    Hong, Ruey-Long
    Pfister, David
    Saba, Nabil F.
    Lee, Se-Hoon
    van Herpen, Carla
    Quadt, Cornelia
    Bootle, Douglas
    Blumenstein, Lars
    Demanse, David
    Delord, Jean-Pierre
    TARGETED ONCOLOGY, 2023, 18 (06) : 853 - 868
  • [35] STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).
    Bendell, Johanna C.
    Tan, Benjamin R.
    Reeves, James Andrew
    Xiong, Henry Q.
    Laeufle, Rita
    Byrtek, Michelle
    Sommer, Nicolas
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal Cancer
    Lee, Keun-Wook
    Han, Sae-Won
    Kim, Tae Won
    Ahn, Joong Bae
    Baek, Ji Yeon
    Cho, Sang Hee
    Lee, Howard
    Kim, Jin Won
    Kim, Ji-Won
    Kim, Tae-You
    Hong, Yong Sang
    Beom, Seung-Hoon
    Cha, Yongjun
    Choi, Yoonjung
    Kim, Seonhui
    Bang, Yung-Jue
    CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 590 - 601
  • [37] A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
    Ana M. Molina
    Thomas E. Hutson
    James Larkin
    Anne M. Gold
    Karen Wood
    Dave Carter
    Robert Motzer
    M. Dror Michaelson
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 181 - 189
  • [38] A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
    Molina, Ana M.
    Hutson, Thomas E.
    Larkin, James
    Gold, Anne M.
    Wood, Karen
    Carter, Dave
    Motzer, Robert
    Michaelson, M. Dror
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (01) : 181 - 189
  • [39] Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC)
    Wainberg, Z.
    Strickler, J.
    Gordon, M.
    Barve, M.
    Wang, L.
    Yue, H.
    Motwani, M.
    Kasichayanula, S.
    Naumovski, L.
    Hamilton, E.
    ANNALS OF ONCOLOGY, 2018, 29 : 66 - 66
  • [40] INTERIM SAFETY RESULTS FROM STEAM: A RANDOMIZED PHASE 2 TRIAL OF SEQUENTIAL AND CONCURRENT FOLFOXIRI-BEVACIZUMAB (BEV) VS FOLFOX-BEV FOR THE FIRST-LINE (1L) TREATMENT (TX) OF PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Hurwitz, H.
    Tan, B.
    Reeves, J.
    Xiong, H.
    Lenz, H.
    Hochster, H.
    Laeufle, R.
    Sommer, N.
    Young, J.
    Byrtek, M.
    Bendell, J.
    ANNALS OF ONCOLOGY, 2014, 25
12345